Analyst Ratings January 23, 2026

Wells Fargo Boosts Clorox Price Target Following $2.25 Billion Acquisition of Purell Maker

Strategic Purchase Expected to Enhance Growth and Portfolio, Although Net Leverage Will Rise

By Avery Klein CLX
Wells Fargo Boosts Clorox Price Target Following $2.25 Billion Acquisition of Purell Maker
CLX

Wells Fargo has increased its price target for Clorox to $115 from $108 after the company announced its acquisition of GOJO Industries, producer of Purell hand sanitizer, for $2.25 billion in cash. The move is viewed as a strategic effort to enhance Clorox's product portfolio and growth prospects. The acquisition is expected to be neutral to earnings in the first year and accretive in the second, with funding via debt increasing leverage to approximately 3.6 times net leverage at closing.

Key Points

  • Wells Fargo increased Clorox’s price target to $115 from $108, maintaining an Equal Weight rating.
  • Clorox is acquiring GOJO Industries, maker of Purell hand sanitizer, for $2.25 billion in cash, netting $1.92 billion after tax benefits.
  • The acquisition is expected to add about 0.5 percentage points to Clorox’s growth, be neutral to earnings per share in year one, and accretive in year two, closing by fiscal year 2026 end.

Investment firm Wells Fargo has raised its price target for Clorox (NYSE: CLX) to $115, up from its prior target of $108, while maintaining an Equal Weight rating on the stock. Current market data indicates Clorox's shares are trading near $112.20, with a price-to-earnings ratio of 17.57. Based on Wells Fargo's Fair Value metrics, the stock is currently considered slightly undervalued.

This upward revision in price expectation follows Clorox’s recent announcement of its plan to acquire GOJO Industries, the manufacturer known for Purell hand sanitizer. The transaction is structured as an all-cash deal valued at $2.25 billion. After accounting for anticipated tax benefits amounting to $330 million, the net purchase price effectively stands at $1.92 billion.

According to Wells Fargo's assessment, this acquisition pertains to a business segment generating a low double-digit percentage of total sales, with an expected mid-single-digit growth rate. The firm anticipates that the purchase will contribute roughly 0.5 percentage points to Clorox’s overall growth trajectory. From a strategic perspective, the acquisition is characterized as an assertive initiative by Clorox to optimize its portfolio via leverage of its balance sheet. Data from InvestingPro suggests Clorox currently maintains moderate debt levels and holds a GOOD financial health rating.

The negotiated net purchase price equates to an adjusted EBITDA multiple of 11.9 times. When factoring in anticipated run-rate cost synergies estimated at $50 million, the effective multiple reduces to 9.1 times EBITDA. To finance the acquisition, Clorox plans to utilize debt, which is projected to elevate its net leverage ratio to about 3.6 times upon deal closure.

Management at Clorox projects the acquisition will have a neutral impact on earnings per share during the first fiscal year following close, transitioning to an accretive effect in the subsequent year. The transaction completion is targeted by the conclusion of Clorox’s fiscal year 2026.

It is noteworthy that Clorox has a long-standing history of dividend payments, sustaining distributions for 56 consecutive years, and currently offers a dividend yield of approximately 4.42%. The company’s next earnings report is scheduled for February 3, 2026.

In related developments, Clorox recently posted fiscal first-quarter earnings results for 2026 that surpassed analyst expectations, recording earnings per share of $0.85 compared to the projected $0.82. Revenue figures also outperformed forecasts, with reported sales of $1.43 billion surpassing the expected $1.39 billion. Following these results, broker Jefferies updated its price target for Clorox to $152 from $155, retaining a Buy rating.

Furthermore, Clorox committed 300,000 volunteer hours to the Realize the Dream initiative, a program honoring Dr. Martin Luther King Jr.’s legacy. Analyst Nik Modi of RBC Capital listed Clorox among top consumer goods investment opportunities, though he acknowledged looming headwinds in the sector.

Collectively, these actions underscore Clorox's proactive approach in portfolio enhancement, strategic acquisition, and community engagement amid a complex economic environment.

Risks

  • The transaction will increase Clorox’s net leverage to approximately 3.6x, which could impact financial flexibility.
  • Earnings per share are expected to remain neutral in the first year, implying limited immediate benefit to profitability.
  • Market conditions in the consumer goods sector are forecasted to be challenging, potentially impacting growth projections.

More from Analyst Ratings

KeyBanc Keeps Cautious View on LyondellBasell After Difficult Quarter, Cites Cash-Flow Limits vs. Dividend Feb 2, 2026 KeyBanc Sticks with Overweight on Murphy USA, Sees Near-Term Upside as Fuel Margins Improve Feb 2, 2026 KeyBanc Stands by Overweight Call on AppFolio, Flags ARPU and Product Drivers for 2026 Feb 2, 2026 KeyBanc Sticks With Overweight on Eastman; $74 Target Reflects Modest Upside Feb 2, 2026 Bernstein Boosts SanDisk Price Target to $1,000 After Robust Q2; Peers Follow Suit Feb 2, 2026